MMP-2/MMP-9 Inhibitor I
(Synonyms: 胶原酶,Metalloproteinase-2/Metalloproteinase-9 Inhibitor I) 目录号 : GC11038
An inhibitor of MMP-2 and MMP-9
Cas No.:193807-58-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
IC50: 310 and 240 nM for MMP-2 and MMP-9, respectively
MMP-2/MMP-9 Inhibitor I is a potent inhibitor of matrix metalloproteinase-2 (MMP-2) and MMP-9.
Matrix metalloproteinase (MMP), a typical metalloproteinase, requires zinc ion at its active sites. As many as 18 kinds of MMP have been identified and cloned and are collectively called the MMP family.
In vitro: MMP-2/MMP-9 inhibitor I was identified as a potent inhibitor of matrix metalloproteinase-2 (MMP-2) and MMP-9 with IC50 values of 310 and 240 nM, respectively. MMP-2/MMP-9 inhibitor I acted by binding zinc at the active site of these MMPs. MMP-2/MMP-9 inhibitor I was found to be able to block MMP-2/MMP-9-dependent invasion in cell culture model [1].
In vivo: Both hydroxamic acid and carboxylic acid analogs of MMP-2/MMP-9 inhibitor I were evaluated for their inhibitory activities in animal cancer models. Results showed that lung colonization of Lewis lung carcinoma cells was suppressed by these inhibitors significantly. In addition, antitumor activity was also observed in the human lung cancer model. Ma44 cells growed as a solid tumor on the peritoneum after being implanted ip, and mice bearing Ma44 eventually died within 3 to 4 weeks. Daily oral administration of compound 5l led to prolonged survival of Ma44-bearing mice [1].
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1] Tamura, Y. ,Watamane, F.,Nakatani, T., et al. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. J. Med. Chem. 41(4), 640-649 (1998).
| Cas No. | 193807-58-8 | SDF | |
| 别名 | 胶原酶,Metalloproteinase-2/Metalloproteinase-9 Inhibitor I | ||
| 化学名 | N-([1,1'-biphenyl]-4-ylsulfonyl)-D-phenylalanine | ||
| Canonical SMILES | O=S(C(C=C1)=CC=C1C2=CC=CC=C2)(N[C@@H](C(O)=O)CC3=CC=CC=C3)=O | ||
| 分子式 | C21H19NO4S | 分子量 | 381.4 |
| 溶解度 | ≤25mM in DMSO | 储存条件 | Store at 4°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6219 mL | 13.1096 mL | 26.2192 mL |
| 5 mM | 0.5244 mL | 2.6219 mL | 5.2438 mL |
| 10 mM | 0.2622 mL | 1.311 mL | 2.6219 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。